CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy
The triple-combination therapy synergistically enhances antitumor efficacy through potent G1/S checkpoint blockade, selective cytotoxicity against ICI-resistant populations, and migration-inhibitory activity, thus establishing CIK-ICI coadministration as a clinically translatable strategy for advanced ovarian malignancies.
Authors
- Peifang Chen
- Jian Pan (ORCID: https://orcid.org/0000-0002-6845-8486)
- Ling Chen (ORCID: https://orcid.org/0000-0003-1485-1626)
- Xiushan Feng
Institutions
- Fujian Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fonc.2025.1670033
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05